[go: up one dir, main page]

WO2001013898A3 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
WO2001013898A3
WO2001013898A3 PCT/GB2000/003309 GB0003309W WO0113898A3 WO 2001013898 A3 WO2001013898 A3 WO 2001013898A3 GB 0003309 W GB0003309 W GB 0003309W WO 0113898 A3 WO0113898 A3 WO 0113898A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
dosage form
pharmaceutical formulations
delaying
delayed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003309
Other languages
English (en)
Other versions
WO2001013898A2 (fr
Inventor
Christian Andina
Niall Fanning
Fiona Palmer
Paul Stark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Priority to EP00954802A priority Critical patent/EP1206250A2/fr
Priority to AU67156/00A priority patent/AU6715600A/en
Priority to JP2001518036A priority patent/JP2003507416A/ja
Priority to CA002380333A priority patent/CA2380333A1/fr
Publication of WO2001013898A2 publication Critical patent/WO2001013898A2/fr
Publication of WO2001013898A3 publication Critical patent/WO2001013898A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à de nouvelles compositions pharmaceutiques conçues pour retarder la libération d'un agent pharmaceutiquement actif. Une formulation médicamenteuse à libération retardée encapsule l'ingrédient actif, qui peut être appliqué sur des microparticules ou se présenter sous forme de comprimés, dans un enrobage retardateur de libération comportant des matières polymères dotées de caractéristiques préétablies de gonflement/perméabilité. Il est en particulier possible d'utiliser des mélanges de polymère d'acide acrylique et/ou d'acrylate, modifiés par des groupes ioniques. Dans une réalisation préférée, un polymère ayant une perméabilité dépendante du pH est utilisé en tant qu'élément plus perméable de l'enrobage. Ces formulations à libération retardée sont administrées sous une seule forme posologique, conjointement à des formulations à libération instantanée ou à libération retenue, de sorte qu'une forme posologique unique, de préférence une forme posologique orale, peut efficacement délivrer deux doses à un patient à des instants différents.
PCT/GB2000/003309 1999-08-26 2000-08-29 Compositions pharmaceutiques Ceased WO2001013898A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00954802A EP1206250A2 (fr) 1999-08-26 2000-08-29 Compositions pharmaceutiques
AU67156/00A AU6715600A (en) 1999-08-26 2000-08-29 Pharmaceutical formulations
JP2001518036A JP2003507416A (ja) 1999-08-26 2000-08-29 医薬製剤
CA002380333A CA2380333A1 (fr) 1999-08-26 2000-08-29 Compositions pharmaceutiques

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15089199P 1999-08-26 1999-08-26
US15088099P 1999-08-26 1999-08-26
US60/151,211 1999-08-26
US60/150,891 1999-08-26
US60/150,880 1999-08-26
US15121199P 1999-08-27 1999-08-27

Publications (2)

Publication Number Publication Date
WO2001013898A2 WO2001013898A2 (fr) 2001-03-01
WO2001013898A3 true WO2001013898A3 (fr) 2001-05-25

Family

ID=27387049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003309 Ceased WO2001013898A2 (fr) 1999-08-26 2000-08-29 Compositions pharmaceutiques

Country Status (4)

Country Link
EP (1) EP1206250A2 (fr)
AU (1) AU6715600A (fr)
CA (1) CA2380333A1 (fr)
WO (1) WO2001013898A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
AU2003296852A1 (en) * 2002-09-18 2004-05-04 Elan Corporation, Plc Multiparticulate modified release composition comprising beraprost
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004039361A1 (fr) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Compositions a liberation intermittente de milnaciprane
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (fr) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US8865197B2 (en) 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
TW200711823A (en) * 2005-09-30 2007-04-01 Primax Electronics Ltd Laminating device and laminating method for use in same
CN108159019A (zh) 2009-12-02 2018-06-15 阿黛尔药物有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN114159391B (zh) * 2021-12-10 2023-05-05 卓和药业集团股份有限公司 重酒石酸卡巴拉汀干混悬剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5470584A (en) * 1991-05-20 1995-11-28 Carderm Capital L.P. Diltiazem formulation
WO2000019985A2 (fr) * 1998-10-01 2000-04-13 Novartis Ag Nouvelles formulations administrees par voie orale et a liberation prolongee

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5470584A (en) * 1991-05-20 1995-11-28 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
WO2000019985A2 (fr) * 1998-10-01 2000-04-13 Novartis Ag Nouvelles formulations administrees par voie orale et a liberation prolongee

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems

Also Published As

Publication number Publication date
EP1206250A2 (fr) 2002-05-22
AU6715600A (en) 2001-03-19
CA2380333A1 (fr) 2001-03-01
WO2001013898A2 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
WO2001013898A3 (fr) Compositions pharmaceutiques
RU2485942C2 (ru) Бупропиона гидробромид и его терапевтические применения
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
FI109451B (fi) Menetelmä lääkeaineen annosteluvälineen valmistamiseksi, joka tuottaa in situ ja vapauttaa kontrolloidusti lääkedispersion
NO975872D0 (no) Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
YU71894A (sh) Novi farmaceutski preparat sa difuziono-osmotskom kontrolom oslobađanja leka i postupak za dobivanje istog
ATE78157T1 (de) Arzneimittel mit langsamer freisetzung.
DK0957900T3 (da) Sammensætninger og fremgangsmåder til topisk påföring af terapeutiske midler
DE69521688D1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
WO2005084639A3 (fr) Systeme d'administration de medicaments polymeres pour des medicaments hydrophobes
DE60124294D1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
RU2007126652A (ru) Композиции и способы стабилизации активных фармацевтических ингредиентов
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
WO2007009806A3 (fr) Formulations posologiques solides de medicaments narcotiques presentant une adsorption buccale amelioree
WO2004110445A1 (fr) Mouche adhesive contenant du phentanyle destinee a etre appliquee sur la muqueuse de la cavite orale
NO20031409L (no) Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse
CA2383212A1 (fr) Dosage oral a liberation regulee destine a l'administration orale
CA2356306A1 (fr) Phosphatidylinositols sulfates, leur preparation et utilisation
EA200601285A1 (ru) Нераспадающаяся твёрдая композиция для перорального применения с высокой дозой растворимых в воде лекарственных средств
WO2006117803A2 (fr) Systemes d'administration transmucosale de medicaments
US6129931A (en) Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
CA2532714A1 (fr) Comprime a liberation prolongee pour l'administration par voie orale
JP2002520269A5 (fr)
CA2187153A1 (fr) Formulations pharmaceutiques effervescentes contenant des microgelules biodegradables a liberation controlee
YU25297A (en) A controlled release formulation for poorly soluble basic drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000954802

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380333

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000954802

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000954802

Country of ref document: EP